Literature DB >> 15542649

Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.

Xinzhen Yang1, Vesko Tomov, Svetla Kurteva, Liping Wang, Xinping Ren, Miroslaw K Gorny, Susan Zolla-Pazner, Joseph Sodroski.   

Abstract

The core of the gp120 glycoprotein from human immunodeficiency virus type 1 (HIV-1) is comprised of three major structural domains: the outer domain, the inner domain, and the bridging sheet. The outer domain is exposed on the HIV-1 envelope glycoprotein trimer and contains binding surfaces for neutralizing antibodies such as 2G12, immunoglobulin G1b12, and anti-V3 antibodies. We expressed the outer domain of HIV-1(YU2) gp120 as an independent protein, termed OD1. OD1 efficiently bound 2G12 and a large number of anti-V3 antibodies, indicating its structural integrity. Immunochemical studies with OD1 indicated that antibody responses against the outer domain of the HIV-1 gp120 envelope glycoprotein are rare in HIV-1-infected human sera that potently neutralize the virus. Surprisingly, such outer-domain-directed antibody responses are commonly elicited by immunization with recombinant monomeric gp120. Immunization with soluble, stabilized HIV-1 envelope glycoprotein trimers elicited antibody responses that more closely resembled those in the sera of HIV-1-infected individuals. These results underscore the qualitatively different humoral immune responses elicited during natural infection and after gp120 vaccination and help to explain the failure of gp120 as an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542649      PMCID: PMC525028          DOI: 10.1128/JVI.78.23.12975-12986.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.

Authors:  Y J Zhang; R Fredriksson; J A McKeating; E M Fenyö
Journal:  Virology       Date:  1997-11-24       Impact factor: 3.616

2.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

3.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

Review 4.  HIV type 1 coreceptors, neutralization serotypes, and vaccine development.

Authors:  J Moore; A Trkola
Journal:  AIDS Res Hum Retroviruses       Date:  1997-06-10       Impact factor: 2.205

5.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Authors:  S W Barnett; S Rajasekar; H Legg; B Doe; D H Fuller; J R Haynes; C M Walker; K S Steimer
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

6.  Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3.

Authors:  B McDougall; M H Nymark; G Landucci; D Forthal; W E Robinson
Journal:  Scand J Immunol       Date:  1997-01       Impact factor: 3.487

7.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

8.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

9.  Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Authors:  R I Connor; B T Korber; B S Graham; B H Hahn; D D Ho; B D Walker; A U Neumann; S H Vermund; J Mestecky; S Jackson; E Fenamore; Y Cao; F Gao; S Kalams; K J Kunstman; D McDonald; N McWilliams; A Trkola; J P Moore; S M Wolinsky
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

Authors:  M K Gorny; T C VanCott; C Hioe; Z R Israel; N L Michael; A J Conley; C Williams; J A Kessler; P Chigurupati; S Burda; S Zolla-Pazner
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

View more
  41 in total

Review 1.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 2.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

3.  Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Roshan Elizabeth Rajan; Yalla Swarupa; Ujjwal Rathore; Anjali Verma; Ranga Udaykumar; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

4.  Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells.

Authors:  Andrés Finzi; Beatriz Pacheco; Xin Zeng; Young Do Kwon; Peter D Kwong; Joseph Sodroski
Journal:  J Virol Methods       Date:  2010-05-13       Impact factor: 2.014

Review 5.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

Review 6.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

7.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

8.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.

Authors:  Hongying Chen; Xiaodong Xu; Hsin-Hui Lin; Ssu-Hsien Chen; Anna Forsman; Marlen Aasa-Chapman; Ian M Jones
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.